Biosensing technology company DexCom Inc (Nasdaq: DXCM) announced on Monday that it has introduced Dexcom Flex, a new continuous glucose monitoring system designed for adults with Type 2 diabetes who are not on intensive insulin therapy, with an initial rollout planned in Germany.

Dexcom Flex is intended for patients using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology across a broader Type 2 diabetes population.

The system provides real-time glucose readings via smartphone, smartwatch or receiver, alongside optional food and activity tracking, personalised behavioural insights and customisable low-glucose alerts to support daily decision-making and help reduce hypoglycaemic events.

Dexcom said the platform is designed to improve understanding of how lifestyle factors and medication affect glucose levels, supporting more personalised diabetes management and behaviour change.

The launch reflects the company's strategy to broaden adoption of CGM technology in Type 2 diabetes care, a rapidly growing patient segment where access to continuous monitoring has historically been limited.